VYNE Therapeutics (VYNE) Net Margin (2017 - 2025)
VYNE Therapeutics (VYNE) posted Net Margin of 8.0% for Q2 2025, down 100.0% on a QoQ basis from 4.0% in Q1 2025, and down 244.0% year-over-year from 5.56% in Q2 2024.
VYNE Therapeutics (VYNE) Net Margin (2017 - 2025) Analysis & Trends
VYNE Therapeutics' Net Margin history runs 9 years deep, the most recent figure standing at 8.0% for Q2 2025.
- Quarterly Net Margin fell 244.0% year-over-year to 8.0% in Q2 2025, while the trailing twelve-month figure through Mar 2026 was 3.41% (up 107.0% YoY) and the FY2025 annual result came in at 44.39%, up 4979.0% from the prior year.
- Net Margin was 8.0% for Q2 2025 at VYNE Therapeutics, down from 4.0% in the prior quarter.
- Across five years, Net Margin topped out at 7507.87% in Q1 2022 and bottomed at 7531.03% in Q4 2022.
- A 5-year average of 863.44% and a median of 47.37% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 1171395 bps — and 2023, when it slumped 751787 bps.
- VYNE Therapeutics' Net Margin stood at 1171.43% in 2021, then sank by 543 bps to 7531.03% in 2022, then jumped by 99 bps to 47.37% in 2023, then jumped by 80 bps to 9.64% in 2024, then increased by 17 bps to 8.0% in 2025.
- Business Quant data shows VYNE's Net Margin at 8.0% in Q2 2025, 4.0% in Q1 2025, and 9.64% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -8.00% |
| Mar 31, 2025 | -4.00% |
| Dec 31, 2024 | -9.64% |
| Jun 30, 2024 | -5.56% |
| Mar 31, 2024 | -8.00% |
| Dec 31, 2023 | -47.37% |
| Sep 30, 2023 | -450.00% |
| Jun 30, 2023 | -20.00% |
| Mar 31, 2023 | -10.00% |
| Dec 31, 2022 | -7,531.03% |
| Sep 30, 2022 | -122.16% |
| Jun 30, 2022 | -191.27% |
| Mar 31, 2022 | 7,507.87% |
| Dec 31, 2021 | -1,171.43% |
| Sep 30, 2021 | -5,269.92% |
| Jun 30, 2021 | -3,131.86% |
| Mar 31, 2021 | -4,206.09% |
| Dec 31, 2020 | -540.85% |
| Sep 30, 2020 | -756.01% |
| Jun 30, 2020 | -1,432.58% |